Market closed

Arcturus Therapeutics Holdings/$ARCT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Ticker

$ARCT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

180

Website

arcturusrx.com

ARCT Metrics

BasicAdvanced

$469M

-

-$2.33

2.64 -

Price and volume

Market cap

$469M

Beta

2.64

52-week high

$45.00

52-week low

$14.30

Average daily volume

397K

Financial strength

Current ratio

4.763

Quick ratio

3.849

Long term debt to equity

9.924

Total debt to equity

9.924

Interest coverage (TTM)

-20,136.75%

Management effectiveness

Return on assets (TTM)

-12.16%

Return on equity (TTM)

-23.12%

Valuation

Price to revenue (TTM)

2.907

Price to book

1.79

Price to tangible book (TTM)

1.79

Price to free cash flow (TTM)

-7.567

Growth

Revenue change (TTM)

-45.85%

Earnings per share change (TTM)

-163.69%

3-year revenue growth (CAGR)

163.14%

3-year earnings per share growth (CAGR)

-32.45%

What the Analysts think about ARCT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.

ARCT Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ARCT Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ARCT News

AllArticlesVideos

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Business Wire·1 week ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Business Wire·2 months ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARCT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arcturus Therapeutics Holdings stock?

Arcturus Therapeutics Holdings (ARCT) has a market cap of $469M as of January 15, 2025.

What is the P/E ratio for Arcturus Therapeutics Holdings stock?

The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of January 15, 2025.

Does Arcturus Therapeutics Holdings stock pay dividends?

No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Arcturus Therapeutics Holdings dividend payment date?

Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.